Jens Christian Jensenius

The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT). / Świerzko, Anna S; Michalski, Mateusz; Sokołowska, Anna; Nowicki, Mateusz; Eppa, Łukasz; Szala-Poździej, Agnieszka; Mitrus, Iwona; Szmigielska-Kapłon, Anna; Sobczyk-Kruszelnicka, Małgorzata; Michalak, Katarzyna; Gołos, Aleksandra; Wierzbowska, Agnieszka; Giebel, Sebastian; Jamroziak, Krzysztof; Kowalski, Marek L; Brzezińska, Olga; Thiel, Steffen; Jensenius, Jens C; Kasperkiewicz, Katarzyna; Cedzyński, Maciej.

In: Frontiers in Immunology, Vol. 9, 2018, p. 2153.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Świerzko, AS, Michalski, M, Sokołowska, A, Nowicki, M, Eppa, Ł, Szala-Poździej, A, Mitrus, I, Szmigielska-Kapłon, A, Sobczyk-Kruszelnicka, M, Michalak, K, Gołos, A, Wierzbowska, A, Giebel, S, Jamroziak, K, Kowalski, ML, Brzezińska, O, Thiel, S, Jensenius, JC, Kasperkiewicz, K & Cedzyński, M 2018, 'The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)', Frontiers in Immunology, vol. 9, pp. 2153. https://doi.org/10.3389/fimmu.2018.02153

APA

Świerzko, A. S., Michalski, M., Sokołowska, A., Nowicki, M., Eppa, Ł., Szala-Poździej, A., Mitrus, I., Szmigielska-Kapłon, A., Sobczyk-Kruszelnicka, M., Michalak, K., Gołos, A., Wierzbowska, A., Giebel, S., Jamroziak, K., Kowalski, M. L., Brzezińska, O., Thiel, S., Jensenius, J. C., Kasperkiewicz, K., & Cedzyński, M. (2018). The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT). Frontiers in Immunology, 9, 2153. https://doi.org/10.3389/fimmu.2018.02153

CBE

Świerzko AS, Michalski M, Sokołowska A, Nowicki M, Eppa Ł, Szala-Poździej A, Mitrus I, Szmigielska-Kapłon A, Sobczyk-Kruszelnicka M, Michalak K, Gołos A, Wierzbowska A, Giebel S, Jamroziak K, Kowalski ML, Brzezińska O, Thiel S, Jensenius JC, Kasperkiewicz K, Cedzyński M. 2018. The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT). Frontiers in Immunology. 9:2153. https://doi.org/10.3389/fimmu.2018.02153

MLA

Vancouver

Author

Świerzko, Anna S ; Michalski, Mateusz ; Sokołowska, Anna ; Nowicki, Mateusz ; Eppa, Łukasz ; Szala-Poździej, Agnieszka ; Mitrus, Iwona ; Szmigielska-Kapłon, Anna ; Sobczyk-Kruszelnicka, Małgorzata ; Michalak, Katarzyna ; Gołos, Aleksandra ; Wierzbowska, Agnieszka ; Giebel, Sebastian ; Jamroziak, Krzysztof ; Kowalski, Marek L ; Brzezińska, Olga ; Thiel, Steffen ; Jensenius, Jens C ; Kasperkiewicz, Katarzyna ; Cedzyński, Maciej. / The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT). In: Frontiers in Immunology. 2018 ; Vol. 9. pp. 2153.

Bibtex

@article{9f8da8008e95483ea1dd664658921c43,
title = "The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)",
abstract = "We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum concentrations of mannose-binding lectin (MBL), CL-LK collectin and MASP-2 as well as activities of MBL-MASP-1 and MBL-MASP-2 complex were made. Serum samples were taken before conditioning chemotherapy, before HSCT and once weekly after (totally 4-5 samples); in minority of subjects also 1 and/or 3 months post transplantation. The results were compared with data from 267 healthy controls and analyzed in relation to clinical data to explore possible associations with cancer and with chemotherapy-induced medical complications. We found a higher frequency of MBL deficiency-associated genotypes (LXA/O or O/O) among multiple myeloma patients compared with controls. It was however not associated with hospital infections or post-HSCT recovery of leukocytes, but seemed to be associated with the most severe infections during follow-up. Paradoxically, high MBL serum levels were a risk factor for prolonged fever and some infections. The first possible association of MBL2 gene 3'-untranslated region polymorphism with cancer (lymphoma) in Caucasians was noted. Heterozygosity for MASP2 gene +359 A>G mutation was relatively frequent in lymphoma patients who experienced bacteremia during hospital stay. The median concentration of CL-LK was higher in myeloma patients compared with healthy subjects. Chemotherapy induced marked increases in serum MBL and MASP-2 concentrations, prolonged for several weeks and relatively slighter decline in CL-LK level within 1 week. Conflicting findings on the influence of MBL on infections following chemotherapy of myeloma and lymphoma have been reported. Here we found no evidence for an association between MBL deficiency and infection during the short period of neutropenia following conditioning treatment before HSCT. However, we noted a possible protective effect of MBL during follow-up, and suspected that to be fully effective when able to act in combination with phagocytic cells after their recovery.",
author = "{\'S}wierzko, {Anna S} and Mateusz Michalski and Anna Soko{\l}owska and Mateusz Nowicki and {\L}ukasz Eppa and Agnieszka Szala-Po{\'z}dziej and Iwona Mitrus and Anna Szmigielska-Kap{\l}on and Ma{\l}gorzata Sobczyk-Kruszelnicka and Katarzyna Michalak and Aleksandra Go{\l}os and Agnieszka Wierzbowska and Sebastian Giebel and Krzysztof Jamroziak and Kowalski, {Marek L} and Olga Brzezi{\'n}ska and Steffen Thiel and Jensenius, {Jens C} and Katarzyna Kasperkiewicz and Maciej Cedzy{\'n}ski",
year = "2018",
doi = "10.3389/fimmu.2018.02153",
language = "English",
volume = "9",
pages = "2153",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)

AU - Świerzko, Anna S

AU - Michalski, Mateusz

AU - Sokołowska, Anna

AU - Nowicki, Mateusz

AU - Eppa, Łukasz

AU - Szala-Poździej, Agnieszka

AU - Mitrus, Iwona

AU - Szmigielska-Kapłon, Anna

AU - Sobczyk-Kruszelnicka, Małgorzata

AU - Michalak, Katarzyna

AU - Gołos, Aleksandra

AU - Wierzbowska, Agnieszka

AU - Giebel, Sebastian

AU - Jamroziak, Krzysztof

AU - Kowalski, Marek L

AU - Brzezińska, Olga

AU - Thiel, Steffen

AU - Jensenius, Jens C

AU - Kasperkiewicz, Katarzyna

AU - Cedzyński, Maciej

PY - 2018

Y1 - 2018

N2 - We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum concentrations of mannose-binding lectin (MBL), CL-LK collectin and MASP-2 as well as activities of MBL-MASP-1 and MBL-MASP-2 complex were made. Serum samples were taken before conditioning chemotherapy, before HSCT and once weekly after (totally 4-5 samples); in minority of subjects also 1 and/or 3 months post transplantation. The results were compared with data from 267 healthy controls and analyzed in relation to clinical data to explore possible associations with cancer and with chemotherapy-induced medical complications. We found a higher frequency of MBL deficiency-associated genotypes (LXA/O or O/O) among multiple myeloma patients compared with controls. It was however not associated with hospital infections or post-HSCT recovery of leukocytes, but seemed to be associated with the most severe infections during follow-up. Paradoxically, high MBL serum levels were a risk factor for prolonged fever and some infections. The first possible association of MBL2 gene 3'-untranslated region polymorphism with cancer (lymphoma) in Caucasians was noted. Heterozygosity for MASP2 gene +359 A>G mutation was relatively frequent in lymphoma patients who experienced bacteremia during hospital stay. The median concentration of CL-LK was higher in myeloma patients compared with healthy subjects. Chemotherapy induced marked increases in serum MBL and MASP-2 concentrations, prolonged for several weeks and relatively slighter decline in CL-LK level within 1 week. Conflicting findings on the influence of MBL on infections following chemotherapy of myeloma and lymphoma have been reported. Here we found no evidence for an association between MBL deficiency and infection during the short period of neutropenia following conditioning treatment before HSCT. However, we noted a possible protective effect of MBL during follow-up, and suspected that to be fully effective when able to act in combination with phagocytic cells after their recovery.

AB - We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum concentrations of mannose-binding lectin (MBL), CL-LK collectin and MASP-2 as well as activities of MBL-MASP-1 and MBL-MASP-2 complex were made. Serum samples were taken before conditioning chemotherapy, before HSCT and once weekly after (totally 4-5 samples); in minority of subjects also 1 and/or 3 months post transplantation. The results were compared with data from 267 healthy controls and analyzed in relation to clinical data to explore possible associations with cancer and with chemotherapy-induced medical complications. We found a higher frequency of MBL deficiency-associated genotypes (LXA/O or O/O) among multiple myeloma patients compared with controls. It was however not associated with hospital infections or post-HSCT recovery of leukocytes, but seemed to be associated with the most severe infections during follow-up. Paradoxically, high MBL serum levels were a risk factor for prolonged fever and some infections. The first possible association of MBL2 gene 3'-untranslated region polymorphism with cancer (lymphoma) in Caucasians was noted. Heterozygosity for MASP2 gene +359 A>G mutation was relatively frequent in lymphoma patients who experienced bacteremia during hospital stay. The median concentration of CL-LK was higher in myeloma patients compared with healthy subjects. Chemotherapy induced marked increases in serum MBL and MASP-2 concentrations, prolonged for several weeks and relatively slighter decline in CL-LK level within 1 week. Conflicting findings on the influence of MBL on infections following chemotherapy of myeloma and lymphoma have been reported. Here we found no evidence for an association between MBL deficiency and infection during the short period of neutropenia following conditioning treatment before HSCT. However, we noted a possible protective effect of MBL during follow-up, and suspected that to be fully effective when able to act in combination with phagocytic cells after their recovery.

U2 - 10.3389/fimmu.2018.02153

DO - 10.3389/fimmu.2018.02153

M3 - Journal article

C2 - 30294330

VL - 9

SP - 2153

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

ER -